Are Spin-Outs Really a Better Bet?
This article was originally published in Start Up
Executive Summary
Big Pharma spin-outs may on average have raised 50% more private money than non-spin-outs over the last five years, but it's not yet clear whether they always deliver better returns on investment. Still, spin-outs remain an investor favorite, and in Europe are becoming the mainstay of a sustainable biopharma industry.
You may also be interested in...
Spain's First Biotech VC
Signs are that Spanish biotech, until now held back by a lack of capital and management expertise, may be about to receive the kick-start it badly needs. Newly-created Ysios Capital Partners is the country's first specialist VC. It's raising a first fund worth €65 million ($92 million)--and it's not alone.
Spain's First Biotech VC
Signs are that Spanish biotech, until now held back by a lack of capital and management expertise, may be about to receive the kick-start it badly needs. Newly-created Ysios Capital Partners is the country's first specialist VC. It's raising a first fund worth €65 million ($92 million)--and it's not alone.
Brane's Brain R&D Spun Out, Seeks Funding
Nikem spun out its R&D assets with about a years' worth of funds to pursue development of its neuropathic pain and Parkinson's disease compounds, which are currently in preclinical development. The company, Brane, is seeking Series A funding.